Elicio Therapeutics, Inc. (ELTX): Total Liabilities
$24.23M
As of 2025-12-31
$23.39M
As of 2026-06-30
+20.8%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.23M | -38.7% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $39.49M | +150.4% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $15.77M | +14.7% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $13.75M | n/c | 2024-03-29, Balance as of period end |
| 2021-12-31 | $15.01M | -89.1% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $137.80M | n/a | 2022-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $24.23M | -38.7% |
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $49.92M | +2.7% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $62.93M | +21.4% |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $9.16M | -50.7% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $4.58M | -34.2% |
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $9.81M | -9.4% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $21.76M | -41.2% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $6.42M | +19.5% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $8.13M | -24.2% |
Compare ELTX, BYSI, CASIF, ONCO side by side · Screen every company in Pharmaceutical Preparations ↗